NYU professor Aswath Damodaran has cautioned that the rush to include newly listed giants such as SpaceX, OpenAI and Anthropic in the S&P 5...

Accenture's slump signals headwinds for Indian IT, with Sandip Sabharwal viewing them as trading plays rather than long-term investments du...

As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

Nippon India Small Cap Fund has topped all equity funds over a decade, delivering a 20.94% CAGR. Despite recent underperformance, its long-...

Indian equity benchmarks extended gains for a fourth consecutive session, reaching their longest winning streak in ten weeks. Retreating cr...

Falling crude oil prices below $80 a barrel are set to prevent further fuel price increases. This development is boosting India's economic ...

TotalEnergies' SATORP refinery in Saudi Arabia is operating at reduced capacity after drone attacks. Full repairs are expected by early 202...

The conditions that created the worst 18 months for small-caps are starting to ease. The US-Iran war is moving towards settlement. Crude pr...

A peace deal, if it comes, will not mean the Gulf region has become stable. It will only mean that current tensions have been paused. The k...

Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...

Indian stock markets are poised for growth. Strong company profits and stable economic factors are supporting this positive outlook. Invest...

India's top three smallcap mutual funds, managing over Rs 1.5 lakh crore, show strong consensus by holding five under-the-radar stocks acro...

Indian equities offer rare discounts for investors. Nippon India Mutual Fund's Equity CIO, Sailesh Raj Bhan, advises accumulating world-cla...

Portfolio Management Services (PMS) offer structural advantages over mutual funds, allowing for concentrated portfolios, significant cash h...

India's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...

Belligerence is back. Both the US and Iran are hitting each other and the statements from both sides do not auger well for a peace deal. Th...

When mid-caps were rising, every concern on valuation was treated as unnecessary caution. Investors who advised patience were told they wer...